These engineered receptors usually contain a monoclonal antibodyderived single-chain variable fragment (scFv) that confers specific binding to a tumor antigen

These engineered receptors usually contain a monoclonal antibodyderived single-chain variable fragment (scFv) that confers specific binding to a tumor antigen. stems from recent innovations in the development of CARs. First-generation CARs comprised an antibody-derived scFv followed by hinge, transmembrane, and